Garcia-Guiñon A, Charry PA, Jimenez M, Sarra J, Delgado I, Segura de la Torre L, Santaliestra M, Garcia-Pintos M, Gonzalez Y, Senin A, Motlló C, Abella E, Cabezudo E, Granell M, Sancho E, Herranz MJ, Seres Y, Gironella M, Soler JA, Marti-Tutusaus JM, Ben Azaiz R, Fernandez de Larrea C
Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma.
Manubens A, Paiva B, Gutiérrez NC, Fernandez M, Calasanz MJ, Rosiñol L, Oriol A, Blanchard MJ, Carrillo E, Benavente C, Martínez-López J, Bargay J, Hernández MT, de la Rubia J, González Y, Paricio M, de Arriba F, Ocio EM, Teruel AI, de la Guia AL, Sirvent M, Gironella M, Sampol A, Arguiñano JM, Cabrera C, Alegre A, Granell M, Cabañas V, Núñez-Córdoba JM, Mateos MV, Lahuerta JJ, San Miguel JF, Bladé J, Rodriguez-Otero P
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.
Lakhwani S, Rosiñol L, Puig N, Pico-Picos MA, Medina-González L, Martínez-López J, Paiva B, Cedena MT, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, González E, Casado LF, Martí JM, Encinas C, De Arriba F, Palomera L, Sampol A, González-Montes Y, Motlló C, De La Cruz J, Alonso R, Mateos MV, Bladé J, Lahuerta JJ, San-Miguel J, Hernández MT
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
González-Calle V, Rodríguez-Otero P, Sureda A, De Arriba F, Reinoso M, Ribas P, González-Rodríguez AP, González Y, Oriol A, Martínez-López J, González MS, Hernández MT, Sirvent M, Cedena T, Puig N, Paiva B, Bladé J, Lahuerta JJ, San-Miguel JF, Mateos MV
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study.
Gonzalez-Montes, Y, Osca-Gelis, G, Rodriguez-Romanos, R, Villavicencio, A, González-Bártulos, M, Llopis, F, Clapes, V, Oriol, A, Sureda, A, Escoda, L, Sarrà, J, Garzó, A, Lloveras, N, Gómez, B, Granada, I, Gallardo, D
CD200 genotype is associated with clinical outcome of patients with multiple myeloma
Medina-Herrera, A, Vazquez, I, Cuenca, I, Rosa-Rosa, JM, Ariceta, B, Jimenez, C, Fernandez-Mercado, M, Larrayoz, MJ, Gutierrez, NC, Fernandez-Guijarro, M, Gonzalez-Calle, V, Rodriguez-Otero, P, Oriol, A, Rosiñol, L, Alegre, A, Escalante, F, De La Rubia, J, Teruel, AI, De Arriba, F, Hernandez, MT, Lopez-Jimenez, J, Ocio, EM, Puig, N, Paiva, B, Lahuerta, JJ, Bladé, J, San Miguel, JF, Mateos, MV, Martinez-Lopez, J, Calasanz, MJ, Garcia-Sanz, R, Rios, R, Sureda, A, Blanchard, MJ, Martinez-Martinez, R, Moraleda, JM, Bargay, J, Gironella, M, Palomera, L, Gonzalez-Montes, Y, Martí, JM, Krsnik, I, Arguiñano, JM, Gonzalez, ME, Gonzalez, AP, Casado, LF
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Alegre A, Gironella M, Escalante F, Bergua JM, Martínez-Chamorro C, López A, González E, Bárez A, Somolinos N, Persona EP, Cabrera AS, Soler A, Rodríguez BI, López JM, González Y, Giménez VC, Sampol A, Muñoz C, Vilanova D, Durán M, Fernández de Larrea C
Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting.
Lakhwani S, Mateos MV, Martínez-López J, Paiva B, Rosiñol Dachs L, Martínez R, Oriol A, Bargay J, González-Montes Y, Gironella M, Encinas C, Martín J, Jarque I, Granell M, Abella E, García-Mateo A, Hernández-Rivas JÁ, Ramila E, Krsnik I, Casado Montero LF, De Arriba F, Palomera L, Sampol A, Moraleda JM, Casanova M, Delgado P, Lafuente A, Amutio E, López-Martínez A, Altés A, Ruíz MÁ, Alegre A, Lopez-Anglada L, De La Cruz J, Alonso Fernández R, Bladé Creixenti J, Lahuerta JJ, San-Miguel J, Hernández MT
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.
Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez I, Granada I, Gallardo D
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma
